Neuroendocrine tumor patients now have wider access to Peptide Receptor Radionuclide Therapy (PRRT) following the January 2018 FDA approval of Lutetium 177 DOTA-TATE (Lu 177). PRRT was approved for the treatment of somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut tumors in adults. Medical experts discuss the advantages and risks of this newly approved treatment method.
